法舒地尔治疗肌萎缩侧索硬化症的安全性、耐受性和疗效(ROCK-ALS):一项2期随机双盲安慰剂对照试验
ROCK-ALS是一项在德国、法国和瑞士19个肌萎缩侧索硬化症中心开展的2期随机双盲安慰剂对照试验,纳入120例受试者,随机接受法舒地尔30 mg、60 mg或安慰剂静脉治疗20天。主要终点为至第180天的安全性(无药物相关严重不良事件的比例)和治疗期间耐受性(未因可疑药物相关不良事件停药的比例)。结果显示法舒地尔安全且耐受性良好,未发现药物相关严重不良事件或死亡。
要点
- 法舒地尔30 mg和60 mg组无药物相关严重不良事件的比例均为1.00,与安慰剂组无显著差异。
- 治疗耐受性(未停药比例):法舒地尔30 mg组1.00,60 mg组0.90,安慰剂组0.93;组间差异未达统计学显著。
- 法舒地尔在肌萎缩侧索硬化症患者中安全且耐受性良好;对疗效结局的影响需在更大型、更长疗程、口服给药及可能更高剂量的试验中探索。
核心结论
- 法舒地尔在肌萎缩侧索硬化症患者中耐受性良好且安全。
- 法舒地尔对疗效结局的影响需在更大型临床试验中探索,采用更长治疗时间、口服给药和可能更高的试验药物剂量。
研究设计与样本
- ROCK-ALS是一项2期、随机、双盲、安慰剂对照试验,在德国、法国和瑞士的19个肌萎缩侧索硬化症中心开展。
- 纳入年龄18-80岁、至少很可能肌萎缩侧索硬化症(依据修订版El Escorial标准)、病程6-24个月、慢肺活量大于预测正常值65%的个体。
- 患者按1:1:1随机接受法舒地尔30 mg(15 mg每日两次)或60 mg(30 mg每日两次)或匹配安慰剂静脉给药,在4周内治疗20天;随访评估在治疗开始后第45、90和180天进行。
- 共同主要终点为至第180天的安全性(定义为无药物相关严重不良事件的比例)和治疗期间耐受性(定义为未因可疑药物相关不良事件停药的比例);主要分析在意向治疗人群(所有进入治疗阶段的参与者)中进行。
- 试验注册于ClinicalTrials.gov(NCT03792490)和Eudra-CT(2017-003676-31),现已完成。
主要发现
- 2019年2月20日至2022年4月20日期间,120名参与者入组并随机化;分配至法舒地尔30 mg组的两人在基线访视前撤回知情同意,因此意向治疗人群包括法舒地尔30 mg组35人、法舒地尔60 mg组39人、安慰剂组44人。
- 无药物相关严重不良事件的估计比例:安慰剂组1.00(95% CI 0.91至1.00),法舒地尔30 mg组1.00(0.89至1.00),法舒地尔60 mg组1.00(0.90至1.00);法舒地尔30 mg与安慰剂的差异为0.00(95% CI -0.11至0.10;p>0.99),法舒地尔60 mg与安慰剂的差异为0.00(-0.10至0.10;p>0.99)。
- 治疗耐受性(未停药的估计比例):安慰剂组0.93(95% CI 0.81至0.99),法舒地尔30 mg组1.00(0.90至1.00),法舒地尔60 mg组0.90(0.76至0.97);法舒地尔30 mg与安慰剂的差异为0.07(95% CI -0.05至0.20;p=0.25),法舒地尔60 mg与安慰剂的差异为-0.03(-0.18至0.10;p=0.70)。
- 发生8例死亡:安慰剂组2例,法舒地尔30 mg组4例,法舒地尔60 mg组2例;最常见的严重不良事件为呼吸衰竭(7例事件)、胃造瘘(5例事件)、肺炎(4例事件)和吞咽困难(4例事件);无严重不良事件或死亡归因于研究治疗。
- 不良事件主要与疾病进展相关,安慰剂组发生139例,法舒地尔30 mg组108例,法舒地尔60 mg组105例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fasudil is a small molecule inhibitor of Rho-associated kinase (ROCK) and is approved for the treatment of subarachnoid haemorrhage. In preclinical studies, fasudil has been shown to attenuate neurodegeneration, modulate neuroinflammation, and foster axonal regeneration. We aimed to investigate the safety, tolerability, and efficacy of fasudil in patients with amyotrophic lateral sclerosis. METHODS: ROCK-ALS was a phase 2, randomised, double-blind, placebo-controlled trial conducted at 19 amyotrophic lateral sclerosis centres in Germany, France, and Switzerland. Individuals (aged 18-80 years) with at least probable amyotrophic lateral sclerosis (as per the revised El Escorial criteria), a disease duration of 6-24 months, and a slow vital capacity greater than 65% of predicted normal were eligible for inclusion. Patients were randomly assigned (1:1:1) to receive 30 mg (15 mg twice daily) or 60 mg (30 mg twice daily) fasudil or matched placebo intravenously for 20 days over a 4-week period. Follow-up assessments were performed at 45, 90, and 180 days after treatment initiation. The co-primary endpoints were safety until day 180 (defined as the proportion without drug-related serious adverse events) and tolerability during the treatment period (defined as the proportion who did not discontinue treatment due to suspected drug-related adverse events). The primary analyses were carried out in the intention-to-treat population, which included all participants who entered the treatment phase. This trial is registered at ClinicalTrials.gov (NCT03792490) and Eudra-CT (2017-003676-31) and is now completed. FINDINGS: Between Feb 20, 2019, and April 20, 2022, 120 participants were enrolled and randomised; two individuals assigned fasudil 30 mg withdrew consent before the baseline visit. Thus, the intention-to-treat population comprised 35 in the fasudil 30 mg group, 39 in the fasudil 60 mg group, and 44 in the placebo group. The estimated proportion without a drug-related serious adverse event was 1·00 (95% CI 0·91 to 1·00) with placebo, 1·00 (0·89 to 1·00) with fasudil 30 mg, and 1·00 (0·90 to 1·00) with fasudil 60 mg; the difference in proportions was 0·00 (95% CI -0·11 to 0·10; p>0·99) for fasudil 30 mg versus placebo and 0·00 (-0·10 to 0·10; p>0·99) for fasudil 60 mg versus placebo. Treatment tolerability (the estimated proportion who did not discontinue) was 0·93 (95% CI 0·81 to 0·99) with placebo, 1·00 (0·90 to 1·00) with fasudil 30 mg, and 0·90 (0·76 to 0·97) with fasudil 60 mg; the difference in proportions was 0·07 (95% CI -0·05 to 0·20; p=0·25) for fasudil 30 mg versus placebo, and -0·03 (-0·18 to 0·10; p=0·70) for fasudil 60 mg versus placebo. Eight deaths occurred: two in the placebo group, four in the fasudil 30 mg group, and two in the fasudil 60 mg group. The most common serious adverse events were respiratory failure (seven events), gastrostomy (five events), pneumonia (four events), and dysphagia (four events). No serious adverse events or deaths were attributed to study treatment. Adverse events, which were mainly related to disease progression, occurred in 139 participants in the placebo group, 108 in the fasudil 30 mg group, and 105 in the fasudil 60 mg group. INTERPRETATION: Fasudil was well tolerated and safe in people with amyotrophic lateral sclerosis. The effect of fasudil on efficacy outcomes should be explored in larger clinical trials with a longer treatment duration, oral administration, and potentially higher dose of the trial drug. FUNDING: Framework of the E-Rare Joint Transnational Call 2016 "Clinical research for new therapeutic uses of already existing molecules (repurposing) in rare diseases".
引用
- Koch JC, Leha A, Bidner H, et al. Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2024. PMID: 39424560. doi:10.1016/S1474-4422(24)00373-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。